Charles River Laboratories International, Inc. (CRL), a leading provider of drug development, non-clinical development, and safety testing services, announced today that its management will participate in two key investor conferences this week to discuss strategic priorities, business developments, and current industry trends.
According to the company's schedule, Charles River will present at the William Blair 46th Annual Growth Stock Conference at 10:00 a.m. CT on June 2, followed by a presentation at the Jefferies Global Healthcare Conference at 9:55 a.m. on June 3. Live webcasts for both events will be accessible through the investor relations section of the company's website, with replays available for approximately two weeks following each presentation.
The company recently completed a CEO transition. Birgit Girshick officially assumed the role of CEO in early May and has established a new strategic framework called "Pathway to Purpose," focusing on modernizing operations, strengthening the scientific portfolio, deepening client relationships, and enhancing profitability. The company previously completed the sale of its CDMO and Cell Solutions businesses to GI Partners on May 6 and plans to finalize the sale of certain European discovery service sites in May to further optimize its business portfolio.
Founded in 1947 and headquartered in Wilmington, Massachusetts, Charles River is a global leader as a contract research organization and one of the largest providers of drug development, non-clinical development, and safety testing services.
The company operates through three segments: Research Models and Services, Discovery and Safety Assessment, and Manufacturing Solutions. Over the past five years, it has supported the research and/or development of over 80% of new drugs approved by the FDA. Financially, Charles River reported first-quarter revenue of $995.8 million, a 1.2% year-over-year increase. Excluding currency impacts and divestitures, organic revenue declined by 1.5%. Non-GAAP earnings per share were $2.06, a 12% decrease from the prior year. The company reaffirmed its full-year 2026 guidance, expecting organic revenue to decline between 0.5% and 1.5% and non-GAAP EPS to be in the range of $10.80 to $11.30. Management anticipates that margin improvements will be weighted toward the second half of the year.
Comments